USD 1.16
(-4.92%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -709 Thousand USD | -314.2% |
2022 | 331 Thousand USD | -46.61% |
2021 | 620 Thousand USD | 238.7% |
2020 | -447 Thousand USD | -6.41% |
2019 | -420.08 Thousand USD | -728.23% |
2018 | -50.72 Thousand USD | 9.33% |
2017 | -55.93 Thousand USD | 27.84% |
2016 | -77.52 Thousand USD | -45.0% |
2015 | -53.46 Thousand USD | 0.0% |
2014 | - USD | 100.0% |
2013 | -4122.00 USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -189 Thousand USD | 12.5% |
2024 Q1 | -216 Thousand USD | -83.05% |
2023 FY | -709 Thousand USD | -314.2% |
2023 Q3 | -200 Thousand USD | 4.31% |
2023 Q2 | -209 Thousand USD | -14.84% |
2023 Q1 | -182 Thousand USD | -287.23% |
2023 Q4 | -118 Thousand USD | 41.0% |
2022 Q3 | -176 Thousand USD | -30.37% |
2022 FY | 331 Thousand USD | -46.61% |
2022 Q1 | 803 Thousand USD | 804.39% |
2022 Q2 | -135 Thousand USD | -116.81% |
2022 Q4 | -47 Thousand USD | 73.3% |
2021 Q2 | 266 Thousand USD | -57.23% |
2021 Q4 | -114 Thousand USD | -148.93% |
2021 FY | 620 Thousand USD | 238.7% |
2021 Q1 | 622 Thousand USD | 0.0% |
2021 Q3 | 233 Thousand USD | -12.41% |
2020 Q3 | - USD | 0.0% |
2020 FY | -447 Thousand USD | -6.41% |
2020 Q2 | - USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2020 Q4 | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 FY | -420.08 Thousand USD | -728.23% |
2019 Q2 | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 FY | -50.72 Thousand USD | 9.33% |
2018 Q1 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2017 FY | -55.93 Thousand USD | 27.84% |
2017 Q4 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 FY | -77.52 Thousand USD | -45.0% |
2015 FY | -53.46 Thousand USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 FY | - USD | 100.0% |
2014 Q1 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 FY | -4122.00 USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 Q3 | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2007 Q1 | - USD | 0.0% |
2007 Q4 | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AIM ImmunoTech Inc. | 160 Thousand USD | 543.125% |
Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -183.6% |
Armata Pharmaceuticals, Inc. | -29.24 Million USD | 97.575% |
Azitra, Inc. | 260.45 Thousand USD | 372.22% |
Can-Fite BioPharma Ltd. | 743 Thousand USD | 195.424% |
Chromocell Therapeutics Corporation | -2.57 Million USD | 72.513% |
Calidi Biotherapeutics, Inc. | -1.25 Million USD | 43.551% |
CEL-SCI Corporation | -3.95 Million USD | 82.088% |
iBio, Inc. | -1.02 Million USD | 30.829% |
Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 108.569% |
MAIA Biotechnology, Inc. | - USD | Infinity% |
Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 94.706% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -494.325% |
NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 108.98% |
NanoViricides, Inc. | -759.01 Thousand USD | 6.589% |
Oragenics, Inc. | -15.45 Million USD | 95.412% |
BiomX Inc. | -1.22 Million USD | 42.264% |
BiomX Inc. | -1.22 Million USD | 42.264% |
Protalix BioTherapeutics, Inc. | 42.51 Million USD | 101.668% |
Palatin Technologies, Inc. | 4.39 Million USD | 116.141% |
Scorpius Holdings, Inc. | -2.21 Million USD | 68.011% |